Security Snapshot

Olema Oncology, Inc. - Class A Common Stock (OLMA) Institutional Ownership

CUSIP: 68062P106

13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

127

Shares (Excl. Options)

77.56MFull value: 77,562,324 · shares · 30 Sep 2026

Price

$8.64

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+288,269
Value change
-$2,849,019
Number of holders
127
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
87,750,694
SEC-reported price per share
$7.92
Insider filing price
$7.92
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • OLMA - Olema Oncology, Inc. - Class A Common Stock is tracked under CUSIP 68062P106.
  • 127 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 183 to 127 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.28BFull value: $1,275,247,437 · USD · 30 Jun 2026
    to
    $667.65MFull value: $667,645,721 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 127 institutions filings for Q3 2026.

Open SEC evidence

Security key

68062P106

13F reference period

Q3 2026

13F holders

127

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
OLMA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 14% +10% $143,813,985 +$24,737,094 12,075,062 +21% FMR LLC 30 Jun 2026
BIOTECHNOLOGY VALUE FUND L P 9.8% $77,238,382 8,939,731 BVF PARTNERS L P/IL 14 Oct 2026
Bain Capital Life Sciences Opportunities IV, L.P. 8.2% -18% $111,425,979 -$15,437,859 7,473,238 -12% Bain Capital Life Sciences Opportunities IV, L.P. 31 Mar 2026
Paradigm Biocapital Advisors LP 10% $37,443,949 7,429,355 Paradigm BioCapital Advisors LP 31 Dec 2024
Janus Henderson Group Ltd. 7.2% -12% $50,038,956 -$6,260,269 6,318,050 -11% JANUS HENDERSON GROUP Ltd. 30 Sep 2026
BlackRock, Inc. 7.1% $78,115,092 6,244,212 BlackRock, Inc. 30 Jun 2026
Invus Global Management, LLC 5.1% $108,693,078 4,461,949 Raymond Debbane 16 Mar 2026
Logos Global Management LP 4.7% $16,172,730 3,208,875 Logos Global Management LP 18 Mar 2025
Point72 Asset Management, L.P. 2.3% $7,781,412 1,543,931 Point72 Asset Management, L.P. 31 Mar 2025
As of 30 Sep 2026, 127 institutional investors reported holding
77.56MFull value: 77,562,324 · shares · 30 Sep 2026
shares of Olema Oncology, Inc. - Class A Common Stock (OLMA). This represents 88% of the company’s total
87.75MFull value: 87,750,694 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
72%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Paradigm Biocapital Advisors LP 9.9% 8,720,576 1.5% $75,345,777
Bain Capital Life Sciences Investors, LLC 8.1% 7,085,249 4.1% $61,216,551
Janus Henderson Group Ltd. 7.2% 6,318,050 0.02% $54,562,060
BVF INC/IL 6% 5,295,893 1.5% $45,756,516
Siren, L.L.C. 5.5% 4,856,949 0.99% $41,964,039
STATE STREET CORP 4.4% 3,847,478 0% $33,242,210
VANGUARD CAPITAL MANAGEMENT LLC 4% 3,513,193 0% $30,353,988
Logos Global Management LP 3.7% 3,208,875 1.6% $27,724,680
Deep Track Capital, LP 2.4% 2,109,951 0.31% $18,229,977
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,969,909 0% $17,023,358
Cormorant Asset Management, LP 2% 1,750,000 1% $15,120,000
DIMENSIONAL FUND ADVISORS LP 1.8% 1,552,837 0% $13,415,730
GOLDMAN SACHS GROUP INC 1.7% 1,485,119 0% $12,831,429
Defilade Capital Management, L.P. 1.6% 1,440,157 2.1% $12,442,956
LIGHTSPEED MANAGEMENT COMPANY, L.L.C. 1.5% 1,355,299 0.58% $11,709,783
VANGUARD PORTFOLIO MANAGEMENT LLC 1.5% 1,327,446 0% $11,469,133
KINGDON CAPITAL MANAGEMENT, L.L.C. 1.4% 1,200,000 1.5% $10,368,000
Duquesne Family Office LLC 1.1% 986,827 0.21% $8,526,000
Point72 Asset Management, L.P. 1% 910,579 0.01% $7,867,403
Qube Research & Technologies Ltd 0.93% 819,155 0.01% $7,077,499
Hudson Bay Capital Management LP 0.8% 700,060 0.03% $6,048,518
Vivo Capital, LLC 0.77% 671,843 0.64% $5,804,724
TWO SIGMA INVESTMENTS, LP 0.75% 660,806 0% $5,709,364
ALGERT GLOBAL LLC 0.72% 631,151 0.07% $5,453,145
Woodline Partners LP 0.67% 588,030 0.02% $5,080,579

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 77,562,324 $667,645,721 -$2,849,019 $8.64 127
2026 Q2 101,921,779 $1,275,247,437 -$15,317,512 $12.51 183
2026 Q1 101,411,965 $1,511,791,691 +$99,305,974 $14.91 193
2025 Q4 90,695,275 $2,267,572,776 +$591,383,435 $25.00 198
2025 Q3 68,238,531 $668,036,044 -$3,229,086 $9.79 124
2025 Q2 70,511,948 $300,429,144 +$22,565,282 $4.26 120
2025 Q1 65,888,228 $247,927,417 -$30,654,965 $3.76 131
2024 Q4 71,278,859 $415,382,388 +$48,509,843 $5.83 154
2024 Q3 58,658,581 $700,332,942 +$12,555,131 $11.94 129
2024 Q2 57,896,539 $626,445,097 +$18,080,243 $10.82 127
2024 Q1 56,110,675 $635,162,151 +$37,635,929 $11.32 125
2023 Q4 51,618,204 $717,066,039 +$56,526,765 $14.03 113
2023 Q3 47,322,813 $584,436,985 +$135,063,720 $12.35 97
2023 Q2 36,408,086 $328,764,561 +$43,216,272 $9.03 86
2023 Q1 33,447,196 $116,103,891 +$1,469,913 $3.47 65
2022 Q4 33,334,567 $81,640,055 -$481,138 $2.45 66
2022 Q3 33,359,693 $92,063,140 -$4,143,577 $2.76 67
2022 Q2 34,202,982 $139,234,855 -$8,391,103 $4.07 70
2022 Q1 36,374,849 $155,206,361 -$17,958,891 $4.26 86
2021 Q4 38,428,075 $359,510,482 -$41,441,250 $9.36 94
2021 Q3 36,741,334 $1,012,524,920 -$19,680,898 $27.56 75
2021 Q2 37,428,321 $1,047,268,923 +$59,576,299 $27.98 68
2021 Q1 35,240,926 $1,158,274,244 -$1,710,105 $33.18 73
2020 Q4 35,073,865 $1,657,230,008 +$1,657,206,010 $48.08 56
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .